GENELUX Corp GNLX
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
GENELUX Corp (GNLX) is a healthcare company listed in the US with a market value of about $84M. In fiscal year 2025 it had revenue of $8000 and net income of -$32M, a net margin of -401812.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -124%.
About GENELUX
GENELUX is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $11M in 2022 to $8000 in 2025, a decline of about 91.0% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 308% over three years (dilution for shareholders). It spends 248138% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $8000 | $8000 | $170000 | $11M |
| Net income | -$32M | -$30M | -$28M | -$5M |
| Free cash flow | -$26M | -$22M | -$21M | -$4M |
| EPS (diluted) | $-0.86 | $-0.95 | $-1.16 | $-0.57 |
| Net margin | -401800.0% | -373400.0% | -16645.3% | -47.0% |
| ROIC | -198.3% | -89.0% | -83.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does GENELUX pay a dividend?
Not currently.
Is GENELUX a good stock to buy?
We do not give buy or sell advice. GENELUX scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.